BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 25939591)

  • 1. Resveratrol reduces the levels of circulating androgen precursors but has no effect on, testosterone, dihydrotestosterone, PSA levels or prostate volume. A 4-month randomised trial in middle-aged men.
    Kjaer TN; Ornstrup MJ; Poulsen MM; Jørgensen JO; Hougaard DM; Cohen AS; Neghabat S; Richelsen B; Pedersen SB
    Prostate; 2015 Sep; 75(12):1255-63. PubMed ID: 25939591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
    Habib FK; Ross M; Tate R; Chisholm GD
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer.
    Stanczyk FZ; Azen CG; Pike MC
    J Steroid Biochem Mol Biol; 2013 Nov; 138():10-6. PubMed ID: 23474436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Resveratrol Reduces the Levels of Circulating Androgen Precursors but has No Effect on Testosterone, Dihydrotestosterone, PSA Levels or Prostate Volume. A 4-Month Randomised Trial in Middle-Aged Men.
    Kaplan SA
    J Urol; 2016 Jun; 195(6):1838. PubMed ID: 27191097
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: a randomized, placebo-controlled trial.
    Idan A; Griffiths KA; Harwood DT; Seibel MJ; Turner L; Conway AJ; Handelsman DJ
    Ann Intern Med; 2010 Nov; 153(10):621-32. PubMed ID: 21079217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.
    Muller RL; Gerber L; Moreira DM; Andriole G; Castro-Santamaria R; Freedland SJ
    Eur Urol; 2012 Nov; 62(5):757-64. PubMed ID: 22658758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.
    Miyoshi Y; Uemura H; Suzuki K; Shibata Y; Honma S; Harada M; Kubota Y
    Andrology; 2017 Mar; 5(2):262-267. PubMed ID: 27813361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dihydrotestosterone and testosterone levels in men screened for prostate cancer: a study of a randomized population.
    Gustafsson O; Norming U; Gustafsson S; Eneroth P; Aström G; Nyman CR
    Br J Urol; 1996 Mar; 77(3):433-40. PubMed ID: 8814852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dutasteride in men receiving testosterone therapy: a randomised, double-blind study.
    Kacker R; Harisaran V; Given L; Miner M; Rittmaster R; Morgentaler A
    Andrologia; 2015 Mar; 47(2):148-52. PubMed ID: 24499051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Obesity-Related Hemodilution of Prostate-Specific Antigen, Dihydrotestosterone, and Testosterone.
    Klaassen Z; Howard LE; Moreira DM; Andriole GL; Terris MK; Freedland SJ
    Prostate; 2017 Apr; 77(5):466-470. PubMed ID: 27990661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a diet rich in phytoestrogens on prostate-specific antigen and sex hormones in men diagnosed with prostate cancer.
    Dalais FS; Meliala A; Wattanapenpaiboon N; Frydenberg M; Suter DA; Thomson WK; Wahlqvist ML
    Urology; 2004 Sep; 64(3):510-5. PubMed ID: 15351581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels.
    Aggarwal R; Weinberg V; Small EJ; Oh W; Rushakoff R; Ryan CJ
    Clin Genitourin Cancer; 2009 Oct; 7(3):E71-6. PubMed ID: 19815485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
    Arnold JT; Le H; McFann KK; Blackman MR
    Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ageratum conyzoides L. inhibits 5-alpha-reductase gene expression in human prostate cells and reduces symptoms of benign prostatic hypertrophy in otherwise healthy men in a double blind randomized placebo controlled clinical study.
    Detering M; Steels E; Koyyalamudi SR; Allifranchini E; Bocchietto E; Vitetta L
    Biofactors; 2017 Nov; 43(6):789-800. PubMed ID: 29048765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia.
    Marberger M; Roehrborn CG; Marks LS; Wilson T; Rittmaster RS
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1323-8. PubMed ID: 16434455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology.
    Labrie F; Bélanger A; Cusan L; Candas B
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2403-9. PubMed ID: 9253308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial.
    Page ST; Lin DW; Mostaghel EA; Marck BT; Wright JL; Wu J; Amory JK; Nelson PS; Matsumoto AM
    J Clin Endocrinol Metab; 2011 Feb; 96(2):430-7. PubMed ID: 21177791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu.
    Takizawa I; Nishiyama T; Hara N; Isahaya E; Hoshii T; Takahashi K
    Prostate; 2010 Sep; 70(13):1395-401. PubMed ID: 20687212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testosterone and dihydrotestosterone levels in the transition zone correlate with prostate volume.
    Pejčić T; Tosti T; Tešić Ž; Milković B; Dragičević D; Kozomara M; Čekerevac M; Džamić Z
    Prostate; 2017 Jul; 77(10):1082-1092. PubMed ID: 28594074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen administration in middle-aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume.
    Pechersky AV; Mazurov VI; Semiglazov VF; Karpischenko AI; Mikhailichenko VV; Udintsev AV
    Int J Androl; 2002 Apr; 25(2):119-25. PubMed ID: 11903662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.